Arizona Institute of Urology — research payments reported

By program year

5 rows

Year	Kind	Amount	Payments
2024	Research	$66,530	2
2022	Research	$20,232	2
2021	Research	$75,194	5
2020	Research	$69,495	6
2019	Research	$46,621	5

Breakdown

Who paid Research payments · program years 2019–2024

AstraZeneca Pharmaceuticals LP $137,714 12 payments
Provepharm Inc. $117,795 4 payments
Boston Scientific Corporation $22,563 4 payments

Studies the money was for Research payments · program years 2019–2024

A Randomised, Double-blind, Placebo-controlled, Multicentre Phase III Study of Olaparib Plus Abiraterone Relative to Placebo Plus Abiraterone as First-line Therapy in Men with Metastatic Castration-resistant Prostate Cancer $134,295 8 payments
PVP-22IC04 and PVP-22IC05 $66,530 2 payments
Pvp-Ic1901 $51,265 2 payments
Rezum II Pivotal Study $22,563 4 payments
A Phase III Open Label Randomized Study to Assess the Efficacy and Safety of Olaparib Lynparza Versus Enzalutamide or Abiraterone Acetate in Men with Metastatic Castration Resistant Prostate Cancer Who Have Failed Prior Treatment with a New Hormonal Agent and Have Homologous Recombination Repair Gene Mutations PROfound $3,419 4 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.